https://doi.org/10.4081/cardio.2023.17
Defining iron replete status in patients with heart failure treated with intravenous iron
Published: December 21, 2023
Abstract Views: 1739
pdf: 56
HTML: 3
HTML: 3
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Iron deficiency is an important therapeutic target in patients with heart failure and reduced ejection fraction (HFrEF). Over the past two decades, several trials of intravenous (IV) iron supplementation in HFrEF have shown favorable effects on symptoms, functional status, and heart failure (HF) hospitalizations...
How to Cite
Talha, K. M., Butler, J., von Haehling, S., Lainscak, M., Ponikowski, P., & Anker, S. D. (2023). Defining iron replete status in patients with heart failure treated with intravenous iron. Global Cardiology, 1(1). https://doi.org/10.4081/cardio.2023.17
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
